ORIC Pharmaceuticals (ORIC) announced data from a Phase 1b trial of enozertinib, ORC-114, at the ESMO Asia Congress 2025. Data in treatment-naive and in previously treated NSCLC patients with EGFR exon 20 mutations were presented at an oral session. Key highlights: Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR , including in patients with active brain metastases; 45% ORR in 2L patients exceeds competitor benchmarks; Competitive safety profile, with no significant off-target toxicity and manageable on-target toxicity, resulting in low discontinuation rate; Enrollment and follow-up continue in 1L patients at selected dose of 80 mg once daily, with next update expected mid-2026 ahead of initiation of potential Phase 3 trial
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Promising Clinical Data and Market Potential Drive Buy Rating for Oric Pharmaceuticals’ Enozertinib
- Oric Pharmaceuticals presents data from enozertinib trial at ESMO Asia
- Oric Pharmaceuticals initiated as Early Stage Biotech at Goldman Sachs
- Buy Rating for Oric Pharmaceuticals: Promising Developments and Enozertinib’s Potential in NSCLC Treatment
- Oric Pharmaceuticals initiated with an Outperform at Evercore ISI